Baird Medical Investment Holdings Ltd
Datakwaliteit: 100%
€ 1,85
▼
€ 0,11
(-5,61%)
Marktkapitalisatie: 67,94 M
Prijs
€ 1,85
Marktkapitalisatie
67,94 M
Dagbereik
€ 1,74 — € 1,99
52-Weeksbereik
€ 0,76 — € 7,26
Volume
506.601
Openen € 1,95
50D / 200D Gem.
€ 1,80
2,60% above
50D / 200D Gem.
€ 2,04
9,49% below
Quick Summary
Belangrijkste Punten
ROE of 3,12% is below average
Debt/Equity of 0,24 — conservative balance sheet
Negative free cash flow of -12,41 M
P/E of 54,84 — premium valuation
Capital efficient — spends only 6,44% of revenue on capex
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
3,12%
Boven sectorgemiddelde (-53,41%)
ROIC5,61%
Net Margin2,75%
Op. Margin10,81%
Veiligheid
Debt / Equity
0,24
Onder sectorgemiddelde (0,31)
Current Ratio1,71
Interest Coverage5,69
Waardering
PE (TTM)
54,84
Boven sectorgemiddelde (-1,48)
P/B Ratio1,91
EV/EBITDA11,57
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 54,8 | -1,5 |
| P/B | 1,9 | 1,6 |
| ROE % | 3,1 | -53,4 |
| Net Margin % | 2,8 | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | 0,2 | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 45,00 M | Net Income (TTM) | 1,24 M |
| ROE | 3,12% | ROA | 1,59% |
| Gross Margin | 87,09% | Operating Margin | 10,81% |
| Net Margin | 2,75% | Free Cash Flow (TTM) | -12,41 M |
| ROIC | 5,61% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,24 | Current Ratio | 1,71 |
| Interest Coverage | 5,69 | Asset Turnover | 0,58 |
| Working Capital | 25,28 M | Tangible Book Value | 35,52 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 54,84 | Forward P/E | N/A |
| P/B Ratio | 1,91 | P/S Ratio | 1,51 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | 11,57 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -18,26% | ||
| Market Cap | 67,94 M | Enterprise Value | 76,35 M |
| Per Share | |||
| EPS (Diluted TTM) | 0,06 | Revenue / Share | 1,23 |
| FCF / Share | -0,34 | OCF / Share | -0,26 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 6,44% | FCF Conversion | -1001,27% |
| SBC-Adj. FCF | N/A | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2024 |
|---|---|
| Revenue | 37,04 M |
| Net Income | 12,60 M |
| EPS (Diluted) | 0,49 |
| Gross Profit | 32,65 M |
| Operating Income | 15,32 M |
| EBITDA | — |
| R&D Expenses | 6,17 M |
| SG&A Expenses | — |
| D&A | 1,14 M |
| Interest Expense | 497.247,0 |
| Income Tax | 1,49 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2024 |
|---|---|
| Total Assets | 77,96 M |
| Total Liabilities | 38,20 M |
| Shareholders' Equity | 39,66 M |
| Total Debt | 4,45 M |
| Cash & Equivalents | — |
| Current Assets | 61,42 M |
| Current Liabilities | 34,62 M |
{"event":"ticker_viewed","properties":{"ticker":"BDMD","listing_kind":"stock","pathname":"/stocks/bdmd","exchange":"Nasdaq","country":"US"}}